After six months of anti-psychotic treatment: Is the improvement in mental health at the expense of physical health?;Tras 6 meses de tratamiento antipsicótico: ¿mejoría de la salud mental a costa de la salud física?

Revista de Psiquiatria y Salud Mental

Volumn 6, Issue 1, 2013, Pages 26-32

  Martín Otaño, Leire ^a   Barbadillo Izquierdo, Laura ^a   Galdeano Mondragón, Ander ^a   Alonso Pinedo, Marta ^a   Querejeta Ayerdi, Imanol ^a,b  

^a HOSPITAL DONOSTIA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Anti psychotic agents; Initial psychotic episode; Metabolic syndrome X; Psychotic disorders

Indexed keywords

GLUCOSE; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ABDOMEN; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; MENTAL HEALTH CARE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; PATIENT MONITORING; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RISK REDUCTION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873324340     PISSN: 18889891     EISSN: 19894600     Source Type: Journal    
DOI: 10.1016/j.rpsm.2012.04.001     Document Type: Article

References (32)

1. S. Saha, D. Chant, and J. McGrath A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64 2007 1123 1131
2. S. Brown, B. Barraclough, and H. Inskip Causes of the excess mortality of schizophrenia Br J Psychiatry 177 2000 212 217
3. C.H. Hennekens, A.R. Hennekens, D. Hollar, and D.E. Casey Schizophrenia and increased risk of cardiovascular disease Am Heart J 150 2005 1115 1121
4. E. Fernandez-Egea, M. Bernardo, T. Donner, I. Conget, E. Parellada, and A. Justicia The metabolic profile of antipsychotic naïve patients with nonaffective psychosis Br J Psychiatry 194 2009 434 438
5. M.C. Ryan, P. Collins, and J.H. Thakore Impaired fasting glucose tolerance in first- episode. Drug-naive patients with schizophrenia Am J Psychiatry 160 2003 284 289
6. B. Kirkpatrick, B.J. Miller, C. García-Rizo, E. Fernandez-Egea, and M. Bernardo Is abnormal glucose tolerance in antipsychotic naïve patients with non-affective psychosis confounded by health habits? Schizoprh Bull 38 2012 280 284
7. B. Kirkpatrick, E. Messias, P.D. Harvey, E. Fernández-Egea, and C.R. Bowie Is schizophrenia a syndrome of accelerating aging? Schizophr Bull 34 2007 1024 1032
8. B. Kirkpatrick El concepto de esquizofrenia Rev Psiquiatr Salud Ment 2 2009 105 107
9. E. Fernandez-Egea, B. Miller, C. García-Rizo, M. Bernardo, and B. Kirkpatrick Metabolic effects of olanzapine in patients with newly diagnosed psychosis J Clin Psychopharmacol 31 2011 154 159
10. R.S. Kahn, W.W. Fleischhacker, H. Boter, M. Davidson, Y. Vergouwe, and L.P. Keet Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial Lancet 371 2008 1085 1097
11. B. Crespo-Facorro, R. Perez-Iglesias, M. Ramirez-Bonilla, O. Martínez-García, J. Llorca, and J. Vazquez-Barquero A practical clinical trial comparing haloperidol, risperidona and olanzapine for the acute treatment of first-episode nonaffective psychosis J Clin Psychiatry 67 2006 1511 1521
12. S. Saddichha, N. Manjunatha, S. Ameen, and S. Akthar Metabolic syndrome in first episode schizophrenia-a randomized doublé-blind controlled, short term prospective study Schizophr Res 101 2008 266 272
13. J.K. Patel, P.F. Buckley, S. Woolson, R.M. Hamer, J.P. McEvoy, and D.O. Perkins Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFÉ study Schizophr Res 111 2009 9 16
14. R. Pérez-Iglesias, I. Mata, J.M. Pelayo-Terán, J.A. Amado, M.T. García-Unzueta, and A. Berja Alteraciones de la glucosa y los lípidos al año de tratamiento en una población no tratada con anterioridad Schizophr Res 107 2009 115 121
15. C. Attux, M.I. Quintana, and A.C. Chaves Weight gain, dyslipemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up Rev Bras Psiquiatr 29 2007 346 349
16. D. Kohen Diabetes Mellitus and schizophrenia: historical perspective Br J Psychiatry 184 Suppl. 47 2004 S64 S66
17. Kirkpatrick B, García-Rizo C, Tang K, Fernández-Egea E, Bernardo M. Cholesterol and triglycerides in antipsychotic-naive patients with nonaffective psychosis. Psychiatry Research 2010;178:559-61.
18. E. Fernandez-Egea, B. Miller, M. Bernardo, T. Donner, and B. Kirkpatrick Parental history of type 2 diabetes in patients with nonaffective psychosis Schizophr Res 98 2008 302 306
19. D.B. Allison, J.L. Mentore, M. Heo, L.P. Chandler, J.C. Cappelleri, and M.C. Infante Antipsychotic induced weight gain: a comprehensive research synthesis Am J Psychiatry 15 1999 1686 1696
20. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologisls; North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes Diabetes Care 27 2004 596 601
21. T. Baptista Body weight gain induced by antipsychotic drugs: mechanisms and managements Acta Psychiatr Scand 100 1999 3 16
22. J.W. Newcomer Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 19 Suppl. 1 2005 1 93
23. H. Jin, J.M. Meyer, and D.V. Jeste Phenomenology of and risk factors for new-onset diabetes-mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases Ann Clin Psychiatry 14 2002 59 64
24. J.W. Newcomer, D.W. Haupt, R. Fucetola, A.K. Melson, J.A. Schweiger, and B.P. Cooper Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia Arch Gen Psychiatry 59 2002 337 345
25. D.S. Dwyer, and D. Donohoe Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake Pharmacol Biochem Behav 75 2003 255 260
26. J. Saiz Ruiz, J. Bobes García, J. Vallejo Ruiloba, J. Giner Ubago, M.P. García-Portillo Grupo de trabajo sobre la salud física del paciente con esquizofrenia Consenso sobre la Salud Física del Paciente con Esquizofrenia de las Sociedades Españolas de Psiquiatría y de Psiquiatría biológica Actas Esp Psiquiatr 36 2008 251 264
27. J. Saiz Ruiz, M.D. Saiz González, A.L. Alegría, E. Mena, J. Luque, and J. Bobes Impacto del Consenso Español sobre la Salud Física del Paciente con Esquizofrenia Rev Psiquiatr Salud Ment 3 2010 137 144
28. D.W. Haupt, L.C. Rosenblatt, E. Kim, R.A. Baker, R. Whitehead, and J.W. Newcomer Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents Am J Psychiatry 166 2009 345 353
29. E.H. Morrato, J.W. Newcomer, S. Kamat, O. Baser, J. Harnett, and B. Cuffel Metabolic screening after the American Associations consensus statement on antipsychotic drugs and diabetes Diabetes Care 32 2009 1037 1042
30. J. Crabb, M. McAllister, and A. Blair Who should swing the stethoscope? An audit of baseline psysical examination and blood monitoring on new patients accepted by an early intervention in psychosis team Early Interv Psychiatry 3 2009 312 316
31. A.J. Mitchell, and T. Selmes Why dont patients attend their appointments? Maintaining engagement with psychiatric services Adv Psychiatr Treat 13 2007 423 434
32. V. Hamilton, M. Luthra, and P. Evans Non attendance in general practice: a questionnaire survey Prim Health Care Res Dev 3 2002 226 230